Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

Geron Corporation's Rytelo gains FDA approval for MDS treatment, with promising sales and positive analyst outlook. Click ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

H.C. Wainwright initiated coverage of Geron (NASDAQ:GERN) with a buy rating, citing the potential of its recently approved ...

Shares of Geron Co. (NASDAQ:GERN – Get Free Report) have been assigned an average recommendation of “Buy” from the eleven ...

Geron (NASDAQ:GERN) shares traded higher in the premarket on Thursday after the company reported better-than-expected earnings for Q3 and announced a $375M funding deal with Royalty Pharma (RPRX) and ...

H.C. Wainwright has recently initiated Geron Corp (GERN) stock to Buy rating, as announced on November 5, 2024, according to Finviz. Earlier, on October 16, 2024, Scotiabank had initiated the stock to ...

Geron (NASDAQ: GERN) Q3 2024 Earnings Call Nov 07, 2024, 8:00 a.m. ET Hello, and welcome to the Geron Corporation ...

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Geron (GERN – Research Report) on November 8 and set a price target of ...

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Geron (GERN – Research Report) and keeping the price target at ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic ...

Geron received $250 million in gross proceeds at closing, with access to an additional $125 million in debt Strengthens balance sheet to support the commercial launch of RYTELO™ in the U.S. and ...